Microbot Medical Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Microbot Medical Inc. is an innovative medical technology firm focused on transforming endovascular procedures through advanced robotic systems. The company primarily engineers sophisticated micro-robotic devices for minimally invasive interventions within the human body's natural and artificial lumens. Its flagship offering, the LIBERTY® Endovascular Robotic System, represents the first FDA-cleared, single-use, remotely operated robotic solution specifically designed for peripheral endovascular procedures. This system aims to enhance precision and safety while significantly reducing radiation exposure for clinical staff and mitigating physical strain. Microbot Medical’s portfolio also includes the NovaCross™ Microcatheter family, acquired in 2022, which can be utilized independently or integrated with the LIBERTY system for specialized procedural kits. The company continues to advance other proprietary platforms, such as the Self-Cleaning Shunt (SCS) technology, intended for treating hydrocephalus and normal pressure hydrocephalus. Following its FDA 510(k) clearance in September 2025, the LIBERTY system commenced a limited market release in the U.S. in the fourth quarter of 2025, with plans for a broader commercial launch in April 2026. A strategic collaboration with Stryker Corporation’s Neurovascular division is ongoing, focusing on integrating neurovascular instruments with the LIBERTY system to develop dedicated robotic kits for specific neurovascular operations. The company maintains a robust intellectual property portfolio, expanding its global patent coverage with recent grants in Japan, complementing existing patents in the U.S., China, and Israel. Microbot Medical Inc. was established in 2010 and operates from Hingham, Massachusetts.
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
Stryker to Report Q1 Earnings: What's in Store for the Stock?
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Microbot Medical Begins Full U.S. Launch of LIBERTY System
Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting